{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-203750","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2025-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.073180+00:00","generated_at":"2026-05-17T06:39:17.806249+00:00","sec_items":["1.01","3.02","3.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Revelation Biosciences raises $9.6M via immediate exercise of existing warrants","bullets":["$9.6M gross proceeds from exercise of 13,065,000 existing warrants at $2.20/share.","Issued 13,065,000 new Class I warrants at same $2.20 price, exercisable after stockholder approval for 5 years.","Existing warrants covered 4,355,000 shares; new warrants cover 13,065,000 shares (higher dilution).","Proceeds to fund clinical development and working capital.","Roth Capital Partners acted as financial advisor for 8% cash fee on gross proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-203750","json":"https://secwatch.observer/filing/0001193125-25-203750.json","markdown":"https://secwatch.observer/filing/0001193125-25-203750.md","text":"https://secwatch.observer/filing/0001193125-25-203750.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000119312525203750/0001193125-25-203750-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000119312525203750/revb-20250911.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:39:17.806249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"126df56e6ccfd1a071dae1219a23485c2544f007","claim":"REVELATION BIOSCIENCES, INC. issued 13,065,000 new common stock warrants (the \"Class I Common Stock Warrants\") of warrant to certain holders of existing Class H Common Stock Warrants for exercise of Existing Warrants at $2.20 per share for aggregate gross proceeds of approximately $9.6 million.","evidence_excerpt":"On September 10, 2025, Revelation Biosciences, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with certain holders (the “Holders”) of 13,065,000 existing Class H Common Stock Warrants exercisable for an aggregate of 4,355,000 shares of its common stock (collectively, the “Existing Warrants”), to exercise their warrants at an exercise price of $2.20 per share, in exchange for the Company’s agreement to issue 13,065,000 new common stock warrants (the “Class I Common Stock Warrants”) as described below.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312525203750/0001193125-25-203750-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"13,065,000 new common stock warrants (the \"Class I Common Stock Warrants\")"},{"label":"Purchaser","value":"certain holders of existing Class H Common Stock Warrants"},{"label":"Consideration","value":"exercise of Existing Warrants at $2.20 per share for aggregate gross proceeds of approximately $9.6 million"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}